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Highlights 
 Schizophrenia is associated to high levels of obesity and metabolic disorders. 
 High rates of disordered eating behaviors may affect schizophrenia patients. 
 The contribution of disordered eating behaviors to an adverse cardiometabolic health 
appears important in this population. 
 More research is needed to help clarify the relationships between eating behaviors and 
weight-related outcomes in schizophrenia. 
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ABSTRACT 
Whilst people with schizophrenia have high levels of obesity and metabolic disease, our 
understanding of their eating behaviors is still limited. Our aim was to evaluate the 
relationships between eating behavior and clinical data in schizophrenia. A cross-sectional 
study including 66 schizophrenia outpatients compared to 81 healthy controls was undertaken. 
Eating behavior was assessed using the shortened 21-item version of the Three-Factor Eating 
Questionnaire (TFEQ-R21). The patients had a mean of 44±11 years; a mean BMI of 30.3±8 
kg/m2 (vs 24±3.3 kg/m
2 
for controls) and a mean duration of illness of 7.2±6 years. All mean 
TFEQ scores were significantly higher in patients (indicating poorer eating behaviors) 
compared to controls after adjustment for age and sex, BMI and smoking status. Among 
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patients, mean TFEQ scores were not significantly different between men and women 
samples. The “cognitive restraint” factor was significantly higher in schizophrenia patients 
with a BMI < 25 than in the group of overweight patients with a BMI > 25. Our findings 
suggest that disordered eating behaviors affect schizophrenia patients regardless of gender or 
duration of disease compared to controls. More research is needed to help clarify the 
relationships between eating behaviors and weight-related outcomes in schizophrenia. 
Key words: Schizophrenia; eating behaviors; eating disorders; obesity; antipsychotics; 
cardiometabolic disorders. 
 
 
1.INTRODUCTION  
People with schizophrenia exhibit a 2-3 increased level of obesity, metabolic 
syndrome, diabetes, and cardiovascular disease compared to the general population 
(Vancampfort et al., 2016). Causes for these increased rates are multifactorial and include 
several unhealthy lifestyle factors (poor diet, low levels of physical activity, substances abuse, 
high rates of smoking), antipsychotic medications side effects and genetic predisposition (De 
Hert et al., 2012; Gardner-Sood et al., 2015; Kouidrat et al., 2013; Malan-Müller et al., 2016; 
Stubbs et al., 2016).  
Eating behaviour and eating disorders (EDs) may correspond to an additional factor 
that could be crucial in the development of cardiometabolic disorders in patients with 
schizophrenia (Ward et al., 2015). In the general population, EDs have been associated with 
profound physical and psychosocial morbidity, obesity, diabetes and an elevated mortality 
risk (Klump et al., 2009; Treasure et al., 2010);(Hudson et al., 2010). Despite growing interest 
in weight gain and metabolic disorders in schizophrenia patients, evaluation of their eating 
behaviour remain underexplored (Kouidrat et al., 2014). However, a previous systematic 
review identified that people with schizophrenia typically have poor dietary habits 
(Dipasquale et al., 2013), although very few studies have used a validated outcome measures 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
4 
 
to consider nutrition intake or specifically focused on EDs (Kouidrat et al., 2014). Thus, there 
is a need for studies using validated measures to investigate eating behaviour and EDs in 
people with schizophrenia, such as the Three-Factor Eating Questionnaire (TFEQ), a widely 
used scale to measure human eating behaviour (Cappelleri et al., 2009). Current evidence 
observed in patients and in animal models indicate that antipsychotics lead to a degree of 
modification in food habits and due to the hyperphagic effects, linked to lack of satiation and 
increased appetite (Blouin et al., 2008; Fernø et al., 2011). Additionally, certain 
antipsychotics such as clozapine and olanzapine have been indicated to increase risk of ED 
symptomology (Brömel et al., 1998; Gebhardt et al., 2007). A previous study among people 
with schizophrenia found that patients treated with atypical antipsychotics exhibit increased 
uncontrolled eating, compared to individuals treated with conventional antipsychotics 
(Sentissi et al., 2009). Another descriptive study indicated that over half of the 40 patients 
with schizophrenia and a BMI greater than or equal to 28 exhibit binge eating symptomology 
(Khazaal et al., 2006).  
Given that EDs may represent a key factor in the development of cardiometabolic 
disorders in schizophrenia, it is important to identify the possible EDs symptomology of this 
population so that effective interventions can be developed. Thus, this study aimed to assess 
eating behaviors, clinical and biological data of a sample of schizophrenia patients compared 
to values of healthy controls. 
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2. METHODS 
2.1 Study design and participants 
The present cross-sectional study meets the standards of the Declaration of Helsinki 
and the local ethic committee approved the study protocol. All study participants provided 
informed consent. Sixty-six consecutive outpatients with schizophrenia or schizoaffective 
disorder established using the Structured Clinical Interview for DSM-IV, were recruited via 
clinical referral within a large community from the psychiatric department of Amiens 
University Hospital (Amiens, France). Patients were compared to 81 healthy controls who 
were recruited from advertisements at the local university and in the local community. All 
participants were aged between 18 and 70 years.  
Exclusion criteria for both patients and controls were a diagnosis of diabetes mellitus, 
alcohol or substance abuse, mental retardation, or a history of neurological disorders by 
reviewing medical files. Individuals were also excluded if they presented poor proficiency in 
French and if they were unable or unwilling to provide their written informed consent. Both, 
schizophrenia patients and controls were examined by an experienced endocrinologist (YK). 
Healthy volunteers were excluded if they presented any psychiatric history or a significant 
medical illness. 
2.2 Eating behavior assessment  
Eating behavior was assessed by using the shortened 21-item version of the Three-
Factor Eating Questionnaire (TFEQ-R21) (Cappelleri et al., 2009; Karlsson et al., 2000). The 
TFEQ is a self-assessment scale used widely in studies of eating behavior in overweight and 
normal weight individuals (Bohrer et al., 2015). For patients who could not read well, the 
TFEQ-R21 questionnaires were read to them. In case of difficulty, they were allowed to ask 
the researcher for clarification. The interview was conducted by a TFEQ-trained psychologist, 
psychiatrist, or dietician.  
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The questionnaire consists of 21 items and covered the following 3 aspects of eating 
motivation: cognitive restraint (6 items investigating the conscious mechanisms for 
restraining food intake to control body weight), emotional eating (6 items investigating 
overeating behaviour in relationship to negative mood states), and uncontrolled eating (9 
items exploring the tendency to lose control over eating when feeling hungry or when 
exposed to external stimuli). Each factor score ranges from 0 to 100. Higher scores indicate 
higher levels of the factor. In another words, it is a measure of eating behaviours and 
cognitions that are consistently associated with disordered eating in general population and 
may represent a risk factor for development of overweight (Fairburn and Harrison, 2003).  
2.3 Demographic, clinical and biological variables  
General health data and anthropometric measures were collected. For schizophrenia 
patients, a complete medical history with detailed information on duration of schizophrenia, 
current smoking status, associated cardiovascular risk factors, pharmacological treatment and 
other relevant medical conditions was collected. Anthropometric measurements (weight, 
height and abdominal circumference) were recorded, and BMI was calculated. Blood pressure 
was measured using a wrist blood pressure monitor after at least 10 min of rest in a sitting 
position. Blood fasting glucose, haemoglobin A1C, creatinine, cholesterol, and triglycerides 
levels were obtained by standard laboratory procedures on blood samples obtained by 
venipuncture after a 12-h overnight fast. 
2.4 Statistical analysis 
Frequencies and descriptive statistics were generated using SAS® software (version 
9.2, SAS Institute Inc., Cary, NC). Data are presented as means ± standard deviation or 
number and percent. Differences in clinical characteristics were compared between patients 
and controls using the Student/Welch or Wilcoxon’s t-test for quantitative data and χ2 or 
Fisher test for qualitative data. Associations between the different clinical variables and 
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medication were computed by using Spearman correlation analyses. Eating behaviors scores 
were compared between patients and controls with the Student/Welch’s t-test and by multiple 
linear regression analysis for adjustment of sex, age, BMI, and smoking status. Differences in 
eating behavior scores were calculated with a confidence interval. Due to small sample size 
and/or departure from normality, eating behavior scores between patients and controls were 
compared within gender strata using Wilcoxon rank sum test. For adjusted analyses, we used 
MANOVA with gender, age, BMI (>25 vs. ≤ 25), smoking status and group (schizophrenia 
vs. control) as independent variables, the three eating variables as dependent variables we 
evaluated the interaction between group and gender and the interaction between BMI and 
group. 
3. RESULTS 
3.1 Participants  
The characteristics of the participants are presented in Table 1. A total of 66 patients 
and 81 healthy controls were included. Forty-three of the patients were male (65%).  In the 
overall sample, mean age was 44±11 years; with a mean BMI of 30.3±8.2 kg/m
2
 and a mean 
duration of disease of 7.2±6 years. The smoking rate reached 70% in the patient sample. 
Patients were older and had a higher BMI compared to controls (24±3.3 kg/m
2
). Almost all 
patients were taking antipsychotics with 38%, 30%, and 25% of the patients taking 
respectively first generation, second-generation antipsychotics or both. About 40% used 
antidepressants and nearly 84% were under anxiolytics treatment.  
3.2 Eating behavior assessment 
Mean TFEQ scores in the two groups are presented in Table 2. The correlations 
between age, disease duration, medication use and TFEQ score in the patient sample were not 
statistically significant. On the three domain scores reported according to gender (male, 
female), all mean scores (restraint, uncontrolled and emotional eating) were higher in 
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schizophrenia patients compared to controls indicating an increased risk of developing an 
eating disorder. 
In agreement with these findings, all the following comparisons were adjusted for age 
and sex, BMI and smoking status. In the control group, women had significantly higher scores 
for “cognitive restraint” and “emotional eating”. In contrast, in the patients group, mean 
scores were not significantly different between men and women samples. The exception was 
for “emotional eating”, in which men patients had a higher mean score. In addition, the 
“cognitive restraint” score was higher in schizophrenia patients with a BMI ≤ 25 than in the 
group of overweight patients with a BMI>25 (respectively, 64.3±15 and 54.3±18; 
Satterthwaite DF=46.3; t=2.35; P =0.02). This difference significantly persisted after 
adjustment, within patients and controls (Table 3). No association has been found between 
BMI and TFEQ scores among controls. 
4. DISCUSSION 
In the current study, we found that schizophrenia patients had higher TFEQ scores on 
the three factors compared to controls, which remained evident after controlling for sex, age, 
BMI and smoking status. Interestingly, various types of EDs including binge eating disorder 
(BED) and night eating syndrome (NES), have been described in schizophrenia (Kouidrat et 
al., 2014; Palmese et al., 2011). In a recent review, the prevalence of eating disorders has been 
found higher in schizophrenia patients than in the general population (Kouidrat et al., 2014). 
Our research together with the wider literature suggests that eating disorders are equally 
evident in men as well as women with schizophrenia, which is in contrast of the general 
population where females are typically more effected (Kouidrat et al., 2014). However, since 
TFEQ is not specific to any eating disorder, our findings should be taken with caution. 
The present results are in line with those of Sentissi et al. 2009, who assessed the 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
9 
 
eating behaviour among 153 schizophrenia patients. This study also did not find any 
difference according to sex but the uncontrolled eating and emotional eating scores increased 
significantly according to the BMI (Sentissi et al., 2009). Among their sample, the 
uncontrolled eating score among individuals treated with second-generation antipsychotics (n 
= 93) was significantly higher than patients treated with conventional antipsychotics (n = 27) 
(Sentissi et al., 2009). In contrast, in our study, no correlation was found between medication 
use or duration of disease and the TFEQ score. Using the Eating Attitudes Test, Fawzi et al. 
found a higher prevalence of disordered eating in 50 antipsychotic naive schizophrenia 
patients than in the control group (30% vs 12%, P = 0.027), suggesting that disordered eating 
may represent a feature of schizophrenia regardless of medication use such as antipsychotics 
(Fawzi and Fawzi, 2012). Indeed, the effects of antipsychotic medication switching as a 
strategy for reducing metabolic problems in people with schizophrenia, did not provide clear 
evidence for better outcomes (Mukundan et al., 2010). 
In our sample, a high mean BMI and high TFEQ scores may indicate a more 
susceptibility to BED, which is in agreement with our previous work, demonstrating that BED 
can frequently affect schizophrenia patients with a prevalence of approximately 10% 
(Kouidrat et al., 2014). Several studies have demonstrated that patients with BED tend to have 
higher scores on cognitive restraint, uncontrolled eating, and emotional eating compared with 
individuals without BED (Bas et al., 2008; Crow et al., 2002; de Zwaan et al., 2003). 
However, we do not use specific scale to assess BED in this study. Thus, we must be cautious 
in interpreting this result. Additionally, we did not observe any differences in TFEQ scores 
according to medication or disease duration, which is in agreement with the results of recent 
studies (Davison, 2013; Sentissi et al., 2009).  
Finally, schizophrenia patients with a normal weight (BMI < 25) exhibited higher 
cognitive restraint score than the group of overweight patients (BMI > 25). This significant 
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relation indicates that a high cognitive restraint score may allow successful weight 
maintenance or, may represent in certain cases a factor for anorexia syndrome (Kouidrat et 
al., 2014). Interestingly, increased cognitive restraint score was associated with more weight 
lost (Urbanek et al., 2015) and better weight loss maintenance (Westenhoefer et al., 2013), 
suggesting that strategies that target cognitive restraint may be important in preventing and 
treating obesity. 
Study results should be interpreted in the context of certain limitations. Indeed, this is 
a cross-sectional study, with a sample constituted of established schizophrenia patients. 
However, our findings support the utilization of the TFEQ-R21 in this population of patients, 
and the effective of patients and controls allowed us to perform a robust analysis of the 
relationship between eating behaviour and the clinical characteristics in patients with 
schizophrenia. The pathophysiology of EDs remains unclear in schizophrenia (Foulon, 2003). 
Several factors may explain the high prevalence of disordered eating behaviours in 
schizophrenia patients including mood disorders, stress, sleep disturbance, socioeconomic 
difficulties and side effects of psychotropic medications (Lundgren et al., 2010). Indeed, 
several psychiatric medications including antipsychotics, antidepressants or mood stabilizers 
may influence eating behaviour and weight gain (Davison, 2013; Gebhardt et al., 2007).  
We did not include patients with diabetes in our study. However, disordered eating 
behaviours may affect around 40% of people with type 2 diabetes (García-Mayor and García-
Soidán, 2016). The co-occurrence of both medical entities may lead to an impairment of 
glycemic control and an increased risk of vascular complications. Given that schizophrenia 
patients exhibit a 2-3 increased rate of diabetes compared to the general population 
(Vancampfort et al., 2016), patients with diabetes may represent a subgroup in need. 
Nevertheless, our study mainly highlights the fact that disordered eating behaviors are 
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frequent among schizophrenia patients. Thus, our findings corroborate that the assessment of 
eating behaviour in schizophrenia is important, since eating disorders are closely related to 
weight gain and cardiometabolic disorders (Kouidrat et al., 2014). Management of EDs may 
emphasize programs including exercise, diet, psycho-behavioral and pharmacological 
approaches (Kouidrat et al., 2015; Stubbs et al., 2016). Lifestyle intervention with healthy diet 
(such as Mediterranean diet) has been associated with better quality of life, psychiatric 
symptoms and cardiometabolic outcomes in a large cohort of 4470 participants living in 
North America (Veronese et al., 2016). Furthermore a randomized controlled study found that 
cognitive and behavioral treatment was effective on binge eating symptomatology and weight 
loss in patients suffering from weight gain associated with antipsychotic treatment (Khazaal et 
al., 2007). Given that, we should sensitize patients, their families and caregivers, to improve 
screening and management of disordered eating behaviors in schizophrenia (Kouidrat et al., 
2016). 
In conclusion, our results show that the TFEQ-R21 is a useful tool for assessing eating 
behavior in patients at high risk of eating disorders. More prospective research is needed to 
help clarify the relationships between eating behaviors and weight-related outcomes that may 
exist among schizophrenia patients. 
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Table 1: Characteristics of schizophrenia patients and controls 
Variables Patients Controls t or χ2 – Statistic test P-value 
N 66 81   
Age (years) 44±11 32±14 t = -5.71 <0.0001 
Sex (M/F) 43/23 24/57 χ2= 18.5 <0.0001 
BMI, kg/ m2 30.3±8.2 24±3.3 t = -6.34 <0.0001 
Current smoker n, (%) 44 (67%) 23 (28%) χ2= 21.5 <0.0001 
Disease duration, years 7.20 ±6 -  - 
Biology     
Serum creatinine (mg/l) 7.7±1.4 -  - 
Fasting glucose (g/l) 0.90±0.3 -  - 
HbA1C (%) 5.4±0.4 -  - 
Total cholesterol (g/l) 1.87±0.41 -  - 
Triglycerides (g/l) 1.71±1.23 -  - 
Medication use (%)     
Antipsychotics 93 -  - 
FGA/SGA/both 38/30/25    
Antidepressants 40 -  - 
Anxiolytics 84 -  - 
Hypnotics 60 -  - 
TFEQ score     
Cognitive restraint (CR) 57.5±17.7 34.6±21.2 t = -7.01 <0.0001 
Uncontrolled eating (UE) 57.5±16.9 35±21.1 t = -7.01 <0.0001 
Emotional eating (EE) 69.1±29.5 41.4±27.2 t = -5.91 <0.0001 
 
Values are mean ± SD 
FGA: first generation antipsychotic, SGA: second-generation antipsychotic 
 
 
Table 2: Eating behavior assessed by the TFEQ in patients and controls 
 
Patients Controls 
TFEQ Score Men 
(n=43) 
Women 
(n=23) 
P-value* Men 
(n=24) 
Women 
(n=57) 
P-value* 
CR 60.2±15.8 52.4±20 W=384 
p=0.1359 
27.1±19.9 37.8±21 W=877.5 
p=0.0453 
UE 58.7±16.7 55.1±17.3 W=441.5 
p=0.4784 
29.5±20.5 37.3±21.1 W=840.5 
p=0.1061 
EE 76.2±26.8 55.8±30.3 W=291.5 
p=0.0058 
27.3±26.3 47.4±25.5 W=877.5 
p=0.0020 
Difference in scores between Patients and Controls after adjustment t-statistic;P-value** 
CR 27.6 [18.7-36.6] t=6.18; p<0.0001 
UE 27.3 [18.6-35.9] t=6.29; p<0.0001 
EE 27.6 [18.7-36.6] t=6.18; p<0.0001 
 
 
Values are mean ± SD, NS: not significant 
CR: Cognitive restraint, UE: Uncontrolled eating, EE: Emotional eating 
*Wilcoxon W-test of Patients versus controls. 
**Multiple linear regression analysis for adjustment of sex, age, BMI and smoking status. 
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Table 3: Difference in scores between BMI≤25 vs. BMI>25 after adjustment, within patients and 
controls 
 
 
TFEQ Score Patients Controls  MANOVA P-value for 
interaction between BMI 
and group 
CR 8.8 [-4.5;22.2] -11.9 [-24.6;0.7]  Wilk’s Lamda=0.936 
F (3, 137)=3.12; P=0.0280 UE 5.8 [-7.6;19.2] 2.2 [-10.5;14.9]  
EE 5.2 [-14.0;24.3] 1.6 [-16.6;19.7]  
 
 
